N@N

Market Maker Surveillance Report. MDGN, GERN, HNR, CYTX, ALXA, KNDI, Winning Stocks With Lowest Price Friction For Friday, Jun

June 22, 2012 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Friday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Friday there were 3684 companies with "abnormal" market making, 3271 companies with positive Friction Factors and 2151 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Friday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. MEDGENICS INC - UNRESTRICTED (OTCBB:MDGN), GERON CORPORATION (NASDAQ:GERN), HARVEST NATURAL RESOURCES IN (NYSE:HNR), CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX), ALEXZA PHARMACEUTICALS INC (NASDAQ:ALXA), KANDI TECHNOLOGIES CORP (NASDAQ:KNDI). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

  Symbol  Change    Percent   Buy Volume   Buy %%    Sell Volume  Sell %%   Net Volume   Friction
  MDGN    $1.810    20.59%    84,856       36.31%    70,644       30.23%    14,212       79      
  GERN    $0.190    13.31%    1,834,480    63.00%    1,057,724    36.32%    776,756      40,882  
  HNR     $4.210    86.27%    3,416,286    34.38%    3,284,423    33.06%    131,863      313     
  CYTX    $0.340    13.72%    493,700      72.33%    178,222      26.11%    315,478      9,279   
  ALXA    $1.230    44.89%    1,531,999    52.03%    1,397,030    47.44%    134,969      1,097   
  KNDI    $0.460    16.97%    133,234      58.28%    95,389       41.72%    37,845       823     

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows MDGN with a dollar gain Friday of $1.81000 and a Friction Factor of 79 shares. That means that it only took 79 more shares of buying than selling to move MDGN higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

MEDGENICS INC - UNRESTRICTED (OTCBB:MDGN) - Medgenics, Inc., a biopharmaceutical company, through its subsidiary Medgenics Medical Israel Ltd., engages in the research and development of products in the field of biotechnology and associated medical equipment. Its Biopump platform technology allows patients to produce their natural human protein therapy for the treatment of a range of chronic diseases, such as anemia and hepatitis C. The company develops EPODURE, a Phase I/II clinical trial product for the treatment of chronic renal anemia; and INFRADURE for the treatment of hepatitis C. It also develops a pipeline of products based on its Biopump technology, such as clotting Factor VIII for the treatment of hemophilia. The companys platform technology also has the potential to treat a range of other therapeutic areas, such as multiple sclerosis, pediatric growth hormone deficiency/muscular atrophy, diabetes, arthritis, wound healing, obesity, chronic pain, and cancer recovery. Medgenics, Inc. was founded in 2000 and is based in Vienna, Virginia.

GERON CORPORATION (NASDAQ:GERN) - Geron Corporation, a biopharmaceutical company, develops biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, and diabetes. It develops a range of anti-cancer therapies based on telomerase inhibitors and telomerase therapeutic vaccines; and diagnostics based on telomerase detection, as well as intends to develop products using telomerase as a marker for cancer diagnosis, prognosis, patient monitoring, and screening. The company develops Imetelstat (GRN163L), which is in Phase I clinical trial for the treatment of chronic lymphoproliferative diseases, solid tumors, multiple myeloma, and non-small cell lung cancer. GRN163L is also in Phase I/II clinical trial to treat breast cancer. The company also develops GRNVAC1 that is in Phase II clinical trial for the treatment of acute myelogenous leukemia. It also develops GRNOPC1, which is in Phase I Trial for treatment of spinal cord injury; and GRNCM1 that is in preclinical stage to treat heart disease and screening. The company has licensing agreement with Merck & Co. to develop telomerase cancer vaccine, which is in Phase I clinical trial for the treatment of prostate and solid tumors; Sienna Cancer Diagnostics to develop a preclinical stage product for the treatment of bladder cancer; and has a collaboration with the University Campus Suffolk to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease. Geron Corporation was founded in 1990 and is based in Menlo Park, California.

HARVEST NATURAL RESOURCES IN (NYSE:HNR) - Harvest Natural Resources, Inc., an independent energy company, engages in the acquisition, exploration, development, production, and disposition of oil and natural gas properties. It holds interests in the Bolivarian Republic of Venezuela, exploration acreage in the Gulf Coast Region of the United States, Antelope prospect in the western United States, and exploration acreage mainly onshore West Sulawesi in the Republic of Indonesia, offshore of the Republic of Gabon, onshore in Oman, and offshore of the Peoples Republic of China. Harvest Natural Resources, through its minority equity investment in Fusion Geophysical, LLC, provides geophysical, geosciences, and reservoir engineering support services. The company was founded in 1988 and is headquartered in Houston, Texas.

CYTORI THERAPEUTICS, INC. (NASDAQ:CYTX) - Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical technologies to enable the practice of regenerative medicine. Regenerative medicines focus on repairing or restoring lost or damaged tissue and cell function. The company develops its product pipeline for the treatments of cardiovascular disease, spinal disc degeneration, gastrointestinal disorders, liver and renal disease, and pelvic health conditions. Its principal products include the Celution family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzymes, and related instrumentation. Its core product, the Celution System, provides physicians with clinical grade stem and regenerative cells for use in the cosmetic and reconstructive surgery market. It also intends to offer the PureGraft System in the U.S as a medical device that prepares autologous fat grafts for use in aesthetic body contouring. The company also sells the StemSource family of products worldwide, including in the United States, for research, as well as for the cryopreservation and storage of ADRCs. It offers the StemSource System as a standalone product, or as a part of a comprehensive suite of systems, equipment, and protocols collectively referred to as a StemSource Cell Bank. The company also develops Celution System for applications in cardiovascular disease, wound healing, gastrointestinal disorders, stress urinary incontinence, liver and renal disease spinal disc degeneration, and pelvic health conditions. Cytori Therapeutics has strategic development and manufacturing joint venture agreement, and other related agreements with Olympus Corporation. The company was founded in 1996 and is headquartered in San Diego, California.

ALEXZA PHARMACEUTICALS INC (NASDAQ:ALXA) - Alexza Pharmaceuticals, Inc., a development stage company, focuses on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. Its product candidates are based on a proprietary technology, the Staccato system that vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery. The companys clinical-stage product candidates comprise AZ-004 (staccato loxapine), which is licensed to Biovail Laboratories International SRL for the acute treatment of agitation in patients with schizophrenia or bipolar disorder; AZ-007 (staccato zaleplon), which completed phase I status for the treatment of insomnia; and AZ-001 (staccato prochlorperazine) and AZ-104 (staccato loxapine, low-dose), phase II product candidates for the treatment of migraine headache. It also develops AZ-002 (Staccato alprazolam), which completed a phase 1 clinical trial in healthy subjects and a phase 2a proof-of-concept clinical trial in panic disorder patients for the treatment of panic attacks; and AZ-003 (Staccato fentanyl) that completed phase 1 clinical trial for the treatment of patients with acute pain, including patients with breakthrough cancer pain and postoperative patients with acute pain episodes. The company was formerly known as Alexza Molecular Delivery Corporation and changed its name to Alexza Pharmaceuticals, Inc. in July 2005. Alexza Pharmaceuticals, Inc. was founded in 2000 and is based in Mountain View, California.

KANDI TECHNOLOGIES CORP (NASDAQ:KNDI) - Kandi Technologies Corp., through its subsidiaries, engages in the design, development, manufacture, and commercialization of off-road vehicles, motorcycles, mini-cars, and special automobile related products. Its off-road vehicles include all-terrain vehicles, specialized utility vehicles, and go-karts. The company sells its products through third-party and independent distributors in the Peoples Republic of China, Asia, North America, Europe, and Australia. Kandi Technologies Corp. is based in Jinhua, the Peoples Republic of China.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net